Quantum BioPharma Submits MS Drug Candidate to UK ILAP Program
July 8th, 2025 1:50 PM
By: Newsworthy Staff
Quantum BioPharma Ltd. has submitted its multiple sclerosis drug candidate, Lucid-MS, to the UK's Innovative Licensing and Access Pathway program, aiming to accelerate treatment access for patients.
Quantum BioPharma Ltd. (NASDAQ: QNTM) announced the submission of its patented multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program by its subsidiary, Huge Biopharma Australia Pty Ltd. The ILAP program is designed to fast-track the development and approval of innovative treatments by bringing together developers, regulators, and the NHS. Lucid-MS represents a first-in-class therapy aimed at addressing demyelination in multiple sclerosis, a key factor in the disease's progression. This move is part of Quantum BioPharma's broader strategy to expedite clinical development and enhance patient access through strategic regulatory pathways. For more details, visit https://ibn.fm/giFkj.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
